22320 Participants Needed

Virtual Screening and Intervention for Adolescent Alcohol Use

MJ
SA
Overseen ByStacy A Sterling, DrPH, MSW
Age: < 18
Sex: Any
Trial Phase: Academic
Sponsor: Kaiser Permanente
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

Do I need to stop my current medications to join the trial?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment Centralized Virtual SBIRT for adolescent alcohol use?

Research suggests that the SBIRT model, which includes screening, brief intervention, and referral to treatment, may be effective for adolescents at risk of substance use disorders. Although more studies are needed, brief interventions have shown promise in helping adolescents reduce risky substance use behaviors.12345

Is the SBIRT approach safe for adolescents?

The SBIRT approach, which includes screening, brief intervention, and referral to treatment, is widely used and considered safe for adolescents. It is an evidence-based method aimed at reducing substance use and preventing related health issues.45678

How is the Centralized Virtual SBIRT treatment different from other treatments for adolescent alcohol use?

Centralized Virtual SBIRT is unique because it uses telehealth to deliver screening, brief intervention, and referral to treatment for adolescents, which can reduce the burden on on-site clinicians and make the process more accessible and sustainable compared to traditional in-person methods.125910

What is the purpose of this trial?

Adolescent alcohol and other drug (AOD) use is a significant public health problem which contributes to high levels of mortality, morbidity and healthcare costs in young people, and identification and early intervention for these problems is critical to improving outcomes. Screening, Brief Intervention and Referral to Treatment (SBIRT) in pediatric primary care is an evidence-based strategy for addressing these problems, but has not been widely and systematically implemented, for a variety of reasons, including lack of training and staffing resources to support its implementation. This pragmatic, Type 1 Hybrid Comparative Effectiveness Implementation study will examine whether a centralized, virtually-delivered modality of SBIRT, rapidly accessible by multiple pediatric primary care clinics, can be cost-effectively implemented to improve early identification and treatment for AOD use and comorbid mental health problems among adolescents identified as being at high or severe risk of AOD use disorder during adolescent Well Visits.

Eligibility Criteria

This trial is for adolescents who may be at high or severe risk of alcohol or other drug use disorders. It's aimed to help with early identification and treatment, including those with comorbid mental health issues.

Inclusion Criteria

I am a teenager at risk of substance use disorder, showing signs of depression or suicidal thoughts.

Exclusion Criteria

I am an adolescent and have had a recent Well Visit.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1 week
1 visit (virtual)

Intervention

Brief interventions delivered virtually by video or telephone by a centralized behavioral health clinician

2 years
Multiple visits (virtual)

Follow-up

Participants are monitored for AOD use, mental health diagnoses, and health services utilization

2 years
1- and 2-year follow-up visits

Treatment Details

Interventions

  • Centralized Virtual SBIRT
Trial Overview The study is testing a centralized virtual SBIRT (Screening, Brief Intervention, and Referral to Treatment) approach in pediatric primary care settings to see if it can effectively identify and manage adolescent substance use.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: CV SBIRTExperimental Treatment1 Intervention
Clinics where brief interventions are delivered virtually by video or telephone by a centralized behavioral health clinician (CV-SBIRT arm)
Group II: Usual Care/Traditional SBIRTActive Control1 Intervention
Clinics where appointment-based brief interventions are delivered by a behavioral health clinician assigned to the clinic (Traditional SBIRT arm)

Centralized Virtual SBIRT is already approved in United States for the following indications:

🇺🇸
Approved in United States as SBIRT for:
  • Alcohol use disorder
  • Substance use disorder
  • Comorbid mental health problems

Find a Clinic Near You

Who Is Running the Clinical Trial?

Kaiser Permanente

Lead Sponsor

Trials
563
Recruited
27,400,000+

Findings from Research

Adolescent substance use poses significant public health risks, emphasizing the need for healthcare providers, especially pediatricians, to enhance their capabilities in screening and intervening for substance use issues.
The updated clinical report provides a simplified approach to Screening, Brief Intervention, and Referral to Treatment (SBIRT) for adolescents, helping pediatricians implement effective prevention and intervention strategies in various healthcare settings.
Substance Use Screening, Brief Intervention, and Referral to Treatment.Levy, SJ., Williams, JF.[2022]
The SBIRT (Screening, Brief Intervention, and Referral to Treatment) model is recommended by the American Academy of Pediatrics as an effective approach for pediatricians to address adolescent substance use, which is a significant public health issue.
Research shows that substance use negatively affects the developing brain, highlighting the importance of early screening and intervention; however, comprehensive studies on the combined effectiveness of all SBIRT components in adolescents are still lacking.
Addressing substance misuse in adolescents: a review of the literature on the screening, brief intervention, and referral to treatment model.Beaton, A., Shubkin, CD., Chapman, S.[2022]
In a study of 2252 publicly insured adolescents aged 12-17, 6.8% reported current substance use, with higher rates among non-Hispanic Black adolescents (15.2%) and those with depressive symptoms (14.4%), highlighting the need for effective screening in pediatric care.
Providers identified barriers to implementing SBIRT, such as lack of confidential screening space and referral options, but expressed support for using technology to improve screening and intervention processes, indicating that integrating SBIRT could help address substance use treatment needs in this population.
Addressing adolescent substance use in an urban pediatric federally qualified health center.Yonek, JC., Velez, S., Satre, DD., et al.[2022]

References

Substance Use Screening, Brief Intervention, and Referral to Treatment. [2022]
Addressing substance misuse in adolescents: a review of the literature on the screening, brief intervention, and referral to treatment model. [2022]
Addressing adolescent substance use in an urban pediatric federally qualified health center. [2022]
Health Care Use Over 3 Years After Adolescent SBIRT. [2020]
SBIRT for adolescent drug and alcohol use: current status and future directions. [2022]
Implementing SBIRT for adolescents within community mental health organizations: A mixed methods study. [2020]
Screening, brief intervention, and referral for alcohol use in adolescents: a systematic review. [2022]
Preparing Advanced Practice Registered Nursing Students to Deliver Adolescent SBIRT for Substance Use. [2019]
The remote brief intervention and referral to treatment model: Development, functionality, acceptability, and feasibility. [2018]
10.United Statespubmed.ncbi.nlm.nih.gov
Interactive Computer Simulation for Adolescent Screening, Brief Intervention, and Referral to Treatment (SBIRT) for Substance Use in an Undergraduate Nursing Program. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security